Phase 4 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years who weigh at least 45 kg
- People who have been diagnosed with a specific type of heart attack (STEMI), where chest pain caused by reduced blood flow to the heart has lasted at least 30 minutes
- People whose heart attack diagnosis is confirmed by a specific pattern on a heart tracing test (ECG) showing abnormal electrical readings across multiple areas of the heart
- People whose chest pain started no more than 12 hours before being enrolled in the trial
- People who are expected to undergo an emergency heart procedure (a procedure to open blocked arteries) no sooner than 30 minutes and no later than 120 minutes after enrollment
Who may not be able to join:
- People who are in a state of severe heart failure causing dangerously low blood pressure (cardiogenic shock)
- People who have active bleeding or are considered to be at high risk of bleeding, including those with serious eye disease affecting blood vessels, or bleeding in the gut or urinary tract within the past month
- People who have had a stroke caused by a blood clot, or a temporary stroke-like episode, within the past 6 months
- People who have ever had a stroke caused by bleeding in the brain
- People with a known bulge (aneurysm) in a blood vessel in the brain
- People who have had a serious injury, surgery, or head injury within the past month
- People suspected of having a tear in the main artery from the heart, or an infection of the heart valves
- People who have had a medical procedure involving a needle in a location difficult to control for bleeding within the past month (confirm with trial site)
- People who are currently taking blood-thinning medication (anticoagulants)
- People with blood pressure that is not well controlled and measures 180/110 mmHg or higher
- People with severely reduced liver or kidney function, based on blood test results outside acceptable ranges (confirm with trial site)
- People with a known allergy to the study drug (r-SAK)
- People who are pregnant, breastfeeding, or planning to become pregnant
- People who have a history of a fully blocked heart artery that was never treated, a previous heart attack, or a previous open-heart bypass surgery
- People who have taken certain blood-thinning tablet medications (other than aspirin and ticagrelor, such as clopidogrel, prasugrel, or cilostazol) since their symptoms began
- People whom the trial doctors consider unsuitable for the trial for other medical reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chunjian Li, PHD, The First Affiliated Hospital with Nanjing Medical University
Phone: +86 13701465229
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
MACE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.